Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cells
BioTime Stock Jumps 22 Percent in Two Days in Wake of Geron Deal
Posted: January 13, 2013 at 8:01 am
The stock price of Biotime, Inc., of
Alameda, Ca., shot up more than 12 percent today following the
announcement of a complex deal that will give it the stem cell assets
of Geron Corp., the first firm to launch a clinical trial for an hESC
therapy.
Geron stock price Jan. 2-8 Google chart |
BioTime stock closed at $3.88, up
43 cents or 12.46 percent. That followed a 9.6 percent gain
yesterday. Geron's stock closed at $1.63, up three cents or 1.9
percent.
43 cents or 12.46 percent. That followed a 9.6 percent gain
yesterday. Geron's stock closed at $1.63, up three cents or 1.9
percent.
News coverage of the deal was light
with our tracking showing only one story so far today on The Scientist magazine web site.
with our tracking showing only one story so far today on The Scientist magazine web site.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on BioTime Stock Jumps 22 Percent in Two Days in Wake of Geron Deal
BioTime Buys Geron’s Stem Cell Assets, Including hESC Clinical Trial
Posted: January 13, 2013 at 8:01 am
Geron Corp., which pioneered the first
clinical trial of an hESC therapy, today sold its stem cell
business to another San Francisco Bay Area firm whose two top
executives were once CEOs at Geron.
Michael West BioTime photo |
The total value of the complex deal was
not clear from the public statements released by Geron and the
acquiring firm, BioTime, Inc., of Alameda, but an unidentified
outside investor is adding $10 million to transaction.
not clear from the public statements released by Geron and the
acquiring firm, BioTime, Inc., of Alameda, but an unidentified
outside investor is adding $10 million to transaction.
In a telephone interview this evening,
Michael West, CEO of BioTime, said that as a result of the deal his
firm will hold 600 patents and patent applications involving stem
cells. He said the aggregation should help in attracting financial
interest in the firm and its efforts.
Michael West, CEO of BioTime, said that as a result of the deal his
firm will hold 600 patents and patent applications involving stem
cells. He said the aggregation should help in attracting financial
interest in the firm and its efforts.
West founded Geron in 1990. BioTime
Acquistion Corp., the BioTime subsidiary that is picking up the Geron
assets, is headed by Tom Okarma, who was Geron's CEO from 1999 to
2011.
Acquistion Corp., the BioTime subsidiary that is picking up the Geron
assets, is headed by Tom Okarma, who was Geron's CEO from 1999 to
2011.
After Okarma left the firm in 2011,
Geron abruptly jettisoned its stem cell business along with the
clinical trial. Geron has been looking since then for a buyer for the
assets.
Geron abruptly jettisoned its stem cell business along with the
clinical trial. Geron has been looking since then for a buyer for the
assets.
Tom Okarma Geron photo |
Only a few months prior to the Geron
decision in 2011, the California stem cell agency had signed a $25
million loan agreement with Geron to support the clinical trial. The
company paid back with interest the amount of the loan that it had
received.
decision in 2011, the California stem cell agency had signed a $25
million loan agreement with Geron to support the clinical trial. The
company paid back with interest the amount of the loan that it had
received.
Information from the two companies did
not specify whether BioTime will begin seeking additional
participants in the clinical trial. Nor did BioTime indicate whether
it would seek additional funding from the state stem cell agency.
not specify whether BioTime will begin seeking additional
participants in the clinical trial. Nor did BioTime indicate whether
it would seek additional funding from the state stem cell agency.
However, West said during the telephone
interview that he has an “open mind” about working with CIRM.
Last year, agency officials indicated an interest in continuing to
support the clinical trial. West said BioTime had already hired some
employees that were laid off by Geron, including its patent attorney.
He said that he hoped to reassemble at least part of Geron's now
scattered stem cell team.
interview that he has an “open mind” about working with CIRM.
Last year, agency officials indicated an interest in continuing to
support the clinical trial. West said BioTime had already hired some
employees that were laid off by Geron, including its patent attorney.
He said that he hoped to reassemble at least part of Geron's now
scattered stem cell team.
According to the Geron press release,
when the deal is officially concluded in September, “it is
anticipated that Geron stockholders would own approximately 21% of
BAC, BioTime would own approximately 72%, and a private investor
would own approximately 7% after an additional $5 million investment
in BAC.”
when the deal is officially concluded in September, “it is
anticipated that Geron stockholders would own approximately 21% of
BAC, BioTime would own approximately 72%, and a private investor
would own approximately 7% after an additional $5 million investment
in BAC.”
For its new operations, BioTime has
leased space in Menlo Park that Geron once used for its stem cell
business.
leased space in Menlo Park that Geron once used for its stem cell
business.
Both firms are publicy traded.
BioTime's stock price closed at $3.45 today and had a 52-week high of
$6.35 and a low of $2.67. Geron closed at $1.60 and had a 52-week
high of $2.99 and a low of 91 cents.
BioTime's stock price closed at $3.45 today and had a 52-week high of
$6.35 and a low of $2.67. Geron closed at $1.60 and had a 52-week
high of $2.99 and a low of 91 cents.
Here is a link to an article in the San
Francisco Business Times about the deal. Here are links to the
BioTime press release, a BioTime FAQ and the Geron press release.
Francisco Business Times about the deal. Here are links to the
BioTime press release, a BioTime FAQ and the Geron press release.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on BioTime Buys Geron’s Stem Cell Assets, Including hESC Clinical Trial
Reverse Engineering Grandpa
Posted: January 13, 2013 at 8:01 am
Stem cells are rarely the subject of
cartoons, but one popped last week from Bizarro.
The cartoon appeared in the San
Francisco Chronicle and elsewhere, including the
Bizarro web site. The image was of a petri dish in a lab with
tiny maternal speck giving parental advice to an even tinier speck:
"You can be anything you want to be when you grow up."
Artist Dan Piraro said the cartoon was his favorite of the
week because of its “strangeness.”
Francisco Chronicle and elsewhere, including the
Bizarro web site. The image was of a petri dish in a lab with
tiny maternal speck giving parental advice to an even tinier speck:
"You can be anything you want to be when you grow up."
Artist Dan Piraro said the cartoon was his favorite of the
week because of its “strangeness.”
Piraro wrote on his blog,
“To use a term common in the
vernacular of geneticists, it’s creepy cool.”
The cartoon did not differentiate
between embryonic and adult cells, much less reprogrammed adult
cells. Using reprogrammed cells in the cartoon would have been even
creepier and cooler, giving new meaning to the 1947 song, “I Am My
Own Grandpa.”(See here and here.)
between embryonic and adult cells, much less reprogrammed adult
cells. Using reprogrammed cells in the cartoon would have been even
creepier and cooler, giving new meaning to the 1947 song, “I Am My
Own Grandpa.”(See here and here.)
(A nod to "Bob" for calling our attention to the cartoon.)
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/gXXLRtG2Sx4/reverse-engineering-grandpa.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Reverse Engineering Grandpa
Mayor’s blood stem cells save leukemia patient
Posted: January 13, 2013 at 5:50 am
In 2006, Linden Mayor David Lossing stopped at a Be the Match national bone marrow registry booth on the University of Michigan campus and had his cheek swabbed to be a potential donor.
Id been giving blood for years, said Lossing, now 49. When I saw the Be the Match booth, it seemed like the next logical thing to do.
It turned out to be a life-changing experience. However, he didnt know that until six and a half years later, when he received a call last October that he was a potential match for international patient with acute leukemia. I had totally forgotten about it until I got the phone call, said Lossing.
The next step was for him to return blood vials to Be the Match, to narrow down the profile. When he found out that he was a good potential donor, he went to Michigan Blood in Grand Rapids for a more extensive physical and testing. I was the best match, he said.
There are two types of extraction processes for obtaining stem cells for a transplant. One is the non-surgical donation of peripheral blood stem cells (PBSC) and the other is a marrow donation through a surgical outpatient procedure in a hospital under anesthesia, which one is used is determined by the recipients physician.
Lossings procedure was the PBSC, a five-day process leading up to the donation. His extraction was set up for Dec. 14-17 and the actual donation day was Dec. 18. I was given shots of filgrastim every day at home to increase the number of blood-forming cells in my bloodstream, said Lossing. Then Suzanne and I went to Grand Rapids for the actual donation process.
The blood was removed through a needle in one arm and passed through a machine that separates the blood-forming cells. The remaining blood was then returned to Lossings system through the other arm. The blood-forming cells are back within four to six weeks, according to Be the Match.
I felt achy and fatigued, but thats all, said Lossing. Every day of the shots, it was a different part of my body that hurt, and finally on day 3, I took Motrin. I was still working at my job throughout the process.
As soon as the bone marrow was extracted, it was immediately taken to Detroit Metro Airport for an international flight to an unknown destination. The patient was expected to receive the parcel on Dec. 19. Lossing had also sent along a birthday card for the patient getting his bone marrow.
The transplant actually resets the clock to a persons birth, said Lossing. He now has a brand new immune system. Hell end up with my blood type and my DNA. Now I have an evil twin. Happy Second Birthday!
Continued here:
Mayor’s blood stem cells save leukemia patient
Posted in Stem Cells
Comments Off on Mayor’s blood stem cells save leukemia patient
Stem cells may hold promise for Lou Gehrig’s disease
Posted: January 12, 2013 at 5:54 am
Public release date: 9-Jan-2013 [ | E-mail | Share ]
Contact: Rachel Seroka rseroka@aan.com 612-928-6129 American Academy of Neurology
SAN DIEGO Apparent stem cell transplant success in mice may hold promise for people with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The results of the study were released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013.
"There have been remarkable strides in stem cell transplantation when it comes to other diseases, such as cancer and heart failure," said study author Stefania Corti, MD, PhD, with the University of Milan in Italy and a member of the American Academy of Neurology. "ALS is a fatal, progressive, degenerative disease that currently has no cure. Stem cell transplants may represent a promising avenue for effective cell-based treatment for ALS and other neurodegenerative diseases."
For the study, mice with an animal model of ALS were injected with human neural stem cells taken from human induced pluripotent stem cells (iPSCs). iPSC are adult cells such as skin cells that have been genetically reprogrammed to an embryonic stem cell-like state. Neurons are a basic building block of the nervous system, which is affected by ALS. After injection, the stem cells migrated to the spinal cord of the mice, matured and multiplied.
The study found that stem cell transplantation significantly extended the lifespan of the mice by 20 days and improved their neuromuscular function by 15 percent.
"Our study shows promise for testing stem cell transplantation in human clinical trials," said Corti.
###
The study was supported by AriSLA - The Italian Foundation for Research on Amyotrophic Lateral Sclerosis (ALS).
Learn more about ALS at http://www.aan.com/patients.
Go here to see the original:
Stem cells may hold promise for Lou Gehrig's disease
Posted in Stem Cells
Comments Off on Stem cells may hold promise for Lou Gehrig’s disease
3D scaffolds ‘support regeneration of complex tissues from stem cells’
Posted: January 12, 2013 at 5:54 am
Washington, January 11 (ANI): Researchers have come up with an innovative method for creating a stretched polymer scaffold that can support complex tissue architectures.
Stem cells can be grown on biocompatible scaffolds to form complex tissues like bone, cartilage, and muscle for repair and regeneration of damaged or diseased tissue.
However, to function properly, the cells must often grow in a specific pattern or alignment.
Zu-yong Wang and a team of researchers from National University of Singapore, Nanyang Technological University, KK Women's and Children's Hospital, and Duke-NUS Graduate Medical School, in Singapore, developed a reproducible method that involves stretching a polymer thin film to produce scaffolds that can support the growth of human mesenchymal stem cells.
The stretching process creates orientated 3-dimensional micro-grooves on the surface of the films, and these formations promote consistent alignment and elongation of stem cells as they grow and develop into tissues on and around the resorbable scaffold.
"The researchers developed a very elegant method to promote cell behaviour," John Jansen, Methods Co-Editor-in-Chief and Professor and Chairman, Department of Biomaterials, Radboud University Nijmegen Medical Center, The Netherlands, said.
The study has been published in the journal Tissue Engineering. (ANI)
Read more:
3D scaffolds 'support regeneration of complex tissues from stem cells'
Posted in Stem Cells
Comments Off on 3D scaffolds ‘support regeneration of complex tissues from stem cells’
3-D biomimetic scaffolds support regeneration of complex tissues from stem cells
Posted: January 12, 2013 at 5:54 am
Jan. 10, 2013 Stem cells can be grown on biocompatible scaffolds to form complex tissues such as bone, cartilage, and muscle for repair and regeneration of damaged or diseased tissue. However, to function properly, the cells must often grow in a specific pattern or alignment. An innovative method for creating a stretched polymer scaffold that can support complex tissue architectures is described in an article in Tissue Engineering, Part C, Methods.
Zu-yong Wang and a team of researchers from National University of Singapore, Nanyang Technological University, KK Women's and Children's Hospital, and Duke-NUS Graduate Medical School, in Singapore, developed a reproducible method that involves stretching a polymer thin film to produce scaffolds that can support the growth of human mesenchymal stem cells. The stretching process creates orientated 3-dimensional micro-grooves on the surface of the films, and these formations promote consistent alignment and elongation of stem cells as they grow and develop into tissues on and around the resorbable scaffold.
The authors present their work in the article, "Biomimetic 3D anisotropic geometries by uniaxial stretch of poly(?-caprolactone) films for mesenchymal stem cell proliferation, alignment and myogenic differentiation."
"The researchers developed a very elegant method to promote cell behavior," says John Jansen, DDS, PhD, Methods Co-Editor-in-Chief and Professor and Chairman, Department of Biomaterials, Radboud University Nijmegen Medical Center, The Netherlands.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Mary Ann Liebert, Inc., Publishers, via AlphaGalileo.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
Read more from the original source:
3-D biomimetic scaffolds support regeneration of complex tissues from stem cells
Posted in Stem Cells
Comments Off on 3-D biomimetic scaffolds support regeneration of complex tissues from stem cells
Safety of Induced Stem Cells Gets a Boost
Posted: January 12, 2013 at 5:54 am
Fears of an immune response to replacement tissues have been overestimated, new research suggests, rejecting previous findings about possible side effects
By Monya Baker and Nature magazine
Induced stem cells have been used to grow and graft skin cells (glowing green) onto a mouse. Image: Masahiro Uda
A paper published in Nature today could dispel a cloud over the hopes of turning a patients own cells into perfectly matched replacement tissues.
Scientists first reported in 2007 that a persons cells could be reprogramed to an embryo-like state, and so could form any type of cell in the body. Medical researchers immediately imagined using these induced pluripotent stem (iPS) cells to create an endless supply of genetically matched replacement tissues to treat a range of diseases: fresh pancreatic tissue for diabetics, for example, or new nerve cells for people with Parkinsons.
The strategy also seemed to offer a way around the ethical complexities of using stem cells derived from human embryos. But then came the worries about possible side effects. Particularly bad news came from a 2011 study showing that iPS cells provoked immune responses when injected into the mice from which they had been derived, casting doubt over one of the key advantages of the cells.
The latest Nature study rejects that conclusion. Masumi Abe, a geneticist at the National Institute of Radiological Sciences in Chiba, Japan, and his team took iPS cells derived from mice and injected them back into the animals. For comparison, they injected other mice with embryonic stem (ES) cells. Yet unlike the 2011 study, which saw iPS cells perform worse than ES cells, the team found no differences between the immune responses of each group. The researchers also transplanted skin and bone-marrow cells derived from iPS or ES cells into mice and achieved similar success rates between the groups. The immune response of both sets of tissues is indistinguishable, says Abe.
Konrad Hochedlinger, a stem-cell scientist at Massachusetts General Hospital in Boston, says that the result will probably calm people down about iPS cells. It is definitely reassuring, he says.
The findings follow another positive study on iPS cells, published late last year, which found that the reprogramming process causes fewer mutations than previously thought. Flora Vaccarino, a neuroscientist at Yale University in New Haven, Connecticut, and her colleagues used high-resolution DNA analysis to compare the genomes of iPS cells and the adult cells from which they were derived. They found that most of the DNA mutations in the iPS cells did not arise during reprogramming but had been present in the parent cells.Yang Xu, a stem-cell scientist at the University of California, San Diego, and co-author of the 2011 study, says that the new work does not dispel all concerns about the immune response provoked by iPS cells.
Xu points out that the skin and bone-marrow cells used in the latest study were not grown from iPS cells in culture, as they would be for clinical use. Instead, the researchers mixed iPS cells into early mouse embryos to make chimaeric embryos. They then used skin and bone-marrow tissues that arose from iPS cells after the embryos grew into adult mice for their transplantation experiments. It is possible, says Xu, that the most immunogenic cells were rejected as the mice developed, which would explain why Abe and his colleagues observed a limited immune response. Transplanting tissues from chimaeric mice is flawed, he says.
Read the original post:
Safety of Induced Stem Cells Gets a Boost
Posted in Stem Cells
Comments Off on Safety of Induced Stem Cells Gets a Boost
Stem Cells Found to Heal Damaged Artery in Lab Study
Posted: January 12, 2013 at 5:54 am
Raises Hope for Developing New Therapies for Many Diseases
Newswise Scientists at the Texas Biomedical Research Institute in San Antonio have for the first time demonstrated that baboon embryonic stem cells can be programmed to completely restore a severely damaged artery. These early results show promise for eventually developing stem cell therapies to restore human tissues or organs damaged by age or disease.
We first cultured the stem cells in petri dishes under special conditions to make them differentiate into cells that are the precursors of blood vessels, and we saw that we could get them to form tubular and branching structures, similar to blood vessels, said John L. VandeBerg, Ph.D., Texas Biomeds chief scientific officer.
This finding gave VandeBerg and his team the confidence to do complex experiments to find out if these cells could actually heal a damaged artery. Human embryonic stem cells were first isolated and grown in 1998.
The results are presented in a manuscript, co-authored by Texas Biomeds Qiang Shi, Ph.D., and Gerald Shatten, Ph.D., of the University of Pittsburgh, published in the January 10, 2013 issue of the Journal of Cellular and Molecular Medicine.
The scientists found that cells derived from embryonic stem cells could actually repair experimentally damaged baboon arteries and are promising therapeutic agents for repairing damaged vasculature of people, according to the authors.
Researchers completely removed the cells that line the inside surface from a segment of artery, and then put cells that had been derived from embryonic stem cells inside the artery. They then connected both ends of the arterial segment to plastic tubing inside a device called a bioreactor which is designed to grow cells and tissues. The scientists then pumped fluid through the artery under pressure as if blood were flowing through it.
The outside of the artery was bathed in another fluid to sustain the cells located there. Three days later, the complex structure of the inner surface was beginning to regenerate, and by 14 days, the inside of the artery had been perfectly restored to its complex natural state. It went from a non-functional tube to a complex fully functional artery.
Just think of what this kind of treatment would mean to a patient who had just suffered a heart attack as a consequence of a damaged coronary artery. And this is the real potential of stem cell regenerative medicinethat is, a treatment with stem cells that regenerates a damaged or destroyed tissue or organ, VandeBerg said.
To show that the artery couldnt heal itself in the absence of stem cells, the researchers took a control arterial segment that also was stripped of the cells on its interior surface, but did not seed it with stem cells. No healing occurred.
Excerpt from:
Stem Cells Found to Heal Damaged Artery in Lab Study
Posted in Stem Cells
Comments Off on Stem Cells Found to Heal Damaged Artery in Lab Study
Stem cells found to heal damaged artery in lab study in baboons
Posted: January 12, 2013 at 5:53 am
Jan. 10, 2013 Scientists at the Texas Biomedical Research Institute in San Antonio have for the first time demonstrated that baboon embryonic stem cells can be programmed to completely restore a severely damaged artery. These early results show promise for eventually developing stem cell therapies to restore human tissues or organs damaged by age or disease.
"We first cultured the stem cells in petri dishes under special conditions to make them differentiate into cells that are the precursors of blood vessels, and we saw that we could get them to form tubular and branching structures, similar to blood vessels," said John L. VandeBerg, Ph.D., Texas Biomed's chief scientific officer.
This finding gave VandeBerg and his team the confidence to do complex experiments to find out if these cells could actually heal a damaged artery. Human embryonic stem cells were first isolated and grown in 1998.
The results are presented in a manuscript, co-authored by Texas Biomed's Qiang Shi, Ph.D., and Gerald Shatten, Ph.D., of the University of Pittsburgh, published in the January 10, 2013 issue of the Journal of Cellular and Molecular Medicine.
The scientists found that cells derived from embryonic stem cells could actually repair experimentally damaged baboon arteries and "are promising therapeutic agents for repairing damaged vasculature of people," according to the authors.
Researchers completely removed the cells that line the inside surface from a segment of artery, and then put cells that had been derived from embryonic stem cells inside the artery. They then connected both ends of the arterial segment to plastic tubing inside a device called a bioreactor which is designed to grow cells and tissues. The scientists then pumped fluid through the artery under pressure as if blood were flowing through it.
The outside of the artery was bathed in another fluid to sustain the cells located there. Three days later, the complex structure of the inner surface was beginning to regenerate, and by 14 days, the inside of the artery had been perfectly restored to its complex natural state. It went from a non-functional tube to a complex fully functional artery.
"Just think of what this kind of treatment would mean to a patient who had just suffered a heart attack as a consequence of a damaged coronary artery. And this is the real potential of stem cell regenerative medicine -- that is, a treatment with stem cells that regenerates a damaged or destroyed tissue or organ," VandeBerg said.
To show that the artery couldn't heal itself in the absence of stem cells, the researchers took a control arterial segment that also was stripped of the cells on its interior surface, but did not seed it with stem cells. No healing occurred.
Stains for proteins that indicate functional characteristics showed that the healed artery had completely normal function and could do everything that a normal artery does in a healthy individual.
Read more:
Stem cells found to heal damaged artery in lab study in baboons
Posted in Stem Cells
Comments Off on Stem cells found to heal damaged artery in lab study in baboons